Abstracts Archive - Page 352 of 2425 - ACR Meeting Abstracts

Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Jean-Charles Mourot¹, Sai Yan Yuen², Mihaela Popescu³ and Nicolas Richard⁴, ¹Université de Montréal, Mont-Royal, QC, Canada, ²Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, ³Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ⁴Hopital Maisonneuve Rosemont, Montreal, QC, Canada
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
Abstract Number: 2429 • ACR Convergence 2023
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Chi Chiu Mok¹, SAU MEI TSE², Kar Li Kelly Chan³ and Wai Han Ma¹, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, China, ³Tuen Mun Hospital, Shatin, China
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…
Abstract Number: 2430 • ACR Convergence 2023
Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim¹, Bryant England³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Punyasha Roul³, Ted R Mikuls⁷, Shirley Cohen-Mekelburg¹, Daniel Clauw⁸, Wyndy Wiitala², Rodney Hayward¹, Jeremy Sussman¹ and Akbar Waljee⁹, ¹VA Ann Arbor; University of Michigan, Ann Arbor, MI, ²VA Ann Arbor, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁹VA Ann Arbor, University of Michigan, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Prior work suggests recent GC use is associated with major adverse cardiovascular events…
Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
Abstract Number: 2426 • ACR Convergence 2023
The Role of β-catenin in Synovial Lining Fibroblast Differentiation
Sonia Presti¹, Gerald F.M. Watts¹, Junning Case¹, Zhu Zhu², Teri Bowman¹, Hung Nguyen¹, Gabriel Nigrovic¹, Ce Gao¹, Kartik Bhamidipati¹, Yuhong Li¹, Suppawat Kongthong¹, Fan Zhang³, Anna Helena Jonsson¹, Accelerating Medicines Partnership Program (AMP RA/SLE) Network⁴, STARS BWH¹, Michael Brenner⁵, Shideh Kazerounian¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²10x Genomics, St. Louis, MO, ³University of Colorado, Aurora, CO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In healthy synovium, lining fibroblasts promote joint health by secreting proteoglycans that lubricate the joint cavity. In rheumatoid arthritis (RA), sublining fibroblasts undergo marked…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2408 • ACR Convergence 2023
The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts
Eloise Norman¹, Clare Fraser², Mitchell Lawlor³ and Anthony Sammel⁴, ¹Prince of Wales Hospital, Randwick, Australia, ²Save Sight Institute, The University of Sydney, Sydney, Australia, ³Sydney and Sydney Eye Hospital, Sydney, Australia, ⁴The Prince of Wales Hospital, Sydney, Australia
Background/Purpose: The rate of positive temporal artery biopsies (TAB) in patients with suspected giant cell arteritis (GCA) varies widely, indicating the need for better pre-test…
Abstract Number: 2435 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics
Marie Binvignat¹, Brenda Miao², Camilla Wibrand³, Monica Yang⁴, Dmitry Rychkov⁵, Emily Flynn⁴, Umair Khan⁴, Joanne Nititham⁶, Alex Carvidi⁴, Melissa Krueger⁴, Erene Niemi⁴, Yang Sun⁴, Gabriella Fragiadakis⁴, David Klatzmann¹, Jeremie SELLAM⁷, Encarnita Mariotti-Ferrandiz¹, Andrew Gross⁴, Chun Jimmie Ye⁴, Atul Butte⁴, Lindsey Criswell⁶, Mary Nakamura⁸ and Marina Sirota⁵, ¹Sorbonne Université, Paris, France, ²University of California San Francisco, Fremont, CA, ³Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, ⁶NIH/NHGRI, Bethesda, MD, ⁷Sorbonne Université APHP, Paris, France, ⁸UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Single cell transcriptional profiling (scRNA-Seq) is valuable in identifying gene signatures and cell subpopulations associated with rheumatoid arthritis (RA). However prior studies have often…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Salma Al Fazazi¹, Fabricio Benavides², Vanesa Calvo Río³, maria rodriguez Vidriales², clara escagedo Cagigas², monica renuncio garcia², luis martin penagos⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Puerta Del Mar, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 2414 • ACR Convergence 2023
Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors
Fernando López¹, Javier Loricera², Ivan Ferraz Amaro³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, Juan I. Villa¹⁰, PALOMA VELA¹¹, Susana Romero Yuste¹², Jose L. Callejas¹³, Eugenio De Miguel¹⁴, Eva Galindez-Agirregoikoa¹⁵, Francisca Sivera¹⁶, Jesús Carlos Fernández López¹⁷, Arturo Llobell¹⁸, Julio Sánchez-Martín¹⁹, Calderon Goercke², Lara Sanchez-Bilbao²⁰, Jose L. Hernández²¹ and Ricardo Blanco²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Torrelavega, Spain, ¹¹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹²Complexo Hospitalario Universitario, Pontevedra, Spain, ¹³Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁴Hospital Universitario La Paz, Madrid, Spain, ¹⁵Basurto University Hospital, Bilbao, Spain, ¹⁶Elda General University Hospital, Elda, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸Parc Tauli University Hospital, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ²⁰Hospital Universitario Marques de Valdecilla, Santander, Spain, ²¹Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). Clinical trial with TCZ in GCA was performed with intravenous (iv)…
Abstract Number: 2421 • ACR Convergence 2023
Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis
Hussein Baalbaki¹, David Dube¹, Carolyn Ross², Stephanie Ducharme-Benard³, Samer Hussein⁴, Rosalie-Selene Meunier⁴, Christian Pagnoux⁵ and Jean-Paul Makhzoum², ¹Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Confirming the diagnosis of giant cell arteritis (GCA) remains challenging. Available diagnostic tests have limited accuracy and availability. Recently, optic nerve sheath enhancement on…
Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Hillary Struthers¹, Emily Vance¹, Kofi Asare-Konadu¹, Holly Rosenzweig² and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Healthcare System, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].